Cells encapsulated in alginate containing a high content of a- l-guluronic acid
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 17, 1995
Issued Date -
N/A
app pub date -
Jul 2, 1993
filing date -
Dec 5, 1989
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Cells such as mammalian or genetically modified cells are encapsulated in high-G alginate that provokes reduced immune response during transplantation or implantation. The alginate contains greater than 50% .alpha.-L-guluronic acid and a minimal amount of mannuronic acid. The amount of .alpha.-L-guluronic acid is preferably at least 65% and more preferably at least 85%. Encapsulation is carried out by suspending cells in a solution of the high-G alginate, forming drops of the solution and contacting the drops with calcium ions to gel the alginate and form microcapsules containing the cells. The microcapsules may contain multiple layers with the high-G alginate preferably forming the outermost layer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully